Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2022-06-28 00:00:00 ET · period of report 2022-06-27 · accession 0000899243-22-024435 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-28 | 2022-06-27 | DFTX | Barrow Robert | CEO, Dir | S - Sale | $0.7 | -36.8K | 3.92M | -0.9% | -$25.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-06-27 | S | D | 36,762 | $0.7 | 3,918,857 | D | — | — | (F2) The Common Shares were sold in one transaction at a price of $0.90 CAD Dollars. This represents the price in United States Dollars using the conversion rate on June 27, 2022. |